This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
by Zacks Equity Research
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.
Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.
Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues
by Zacks Equity Research
Acadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording wider-than-expected loss per share and better-than-expected revenue figures owing to the sales of Nuplazid.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.
Amarin (AMRN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Amarin (AMRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
by Zacks Equity Research
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
by Zacks Equity Research
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
GSK Signs Deal to Develop Antibodies for Treating Cancer
by Zacks Equity Research
GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
by Zacks Equity Research
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
by Zacks Equity Research
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.
Why Amarin (AMRN) Stock Might be a Great Pick
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named
by Zacks Equity Research
The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
by Zacks Equity Research
Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the same.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
by Zacks Equity Research
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.
Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.